The FDA announced it will allow the use of plasma donations from patients who have recovered from COVID-19, the disease caused by the novel coronavirus, through emergency Investigational New Drug Applications that can be processed within four to eight hours to treat the sickest patients. Clinical studies are needed to validate the method, which has shown promise anecdotally.
FDA to facilitate use of convalescent plasma for COVID-19
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.